|Bid||0.00 x 3000|
|Ask||59.00 x 1400|
|Day's range||56.88 - 57.73|
|52-week range||48.25 - 79.55|
|Beta (3Y monthly)||1.66|
|PE ratio (TTM)||16.57|
|Earnings date||11 Feb 2019 - 15 Feb 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||69.00|
Of the ten analysts covering DaVita (DVA), five have given it “buy” or higher ratings, four have given it “holds,” and one has given it a “sell.”
In the third quarter, DaVita’s (DVA) patient care and other costs rose YoY (year-over-year) to $2.06 billion from $1.95 billion. Its gross margin expanded YoY to 27.52% from 25.41%. Expected trends
DaVita’s (DVA) two major business divisions are Kidney Care (DaVita Kidney Care) and DMG (DaVita Medical Group). The Kidney Care division includes its US dialysis and associated lab services, ancillary services, and strategic initiatives such as pharmacy services, disease management, vascular access services, and clinical research programs.
NEW YORK, Dec. 07, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
DaVita (DVA) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
DaVita was set to give back gains at Wall Street's open Thursday after the dialysis provider reported third-quarter earnings and revenue that missed analysts' expectations.
DaVita HealthCare (DVA) delivered earnings and revenue surprises of -37.08% and -2.47%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Denver-based company said it had a loss of 82 cents. Earnings, adjusted to account for discontinued operations and non-recurring costs, came to 56 cents per share. The results ...
The Nasdaq and S&P 500 led an early rally fueled by election results and earnings news, as Caterpillar and United Health drove the Dow.
Democratic control of the House likely means that Obamacare is safe -- a positive for hospitals and other companies.
It’s human nature to shy away from uncertainty, so with the midterm elections behind us, stocks are gaining ground again.
DaVita shelled out $66.6 million of the more than $110 million spent by the industry lobbying against Proposition 8, which was defeated by California voters on Tuesday.
DaVita has shelled out $66.6 million of the more than $110 million spent by the industry lobbying against Proposition 8, which if passed Tuesday, would cap the amount of money dialysis providers in the state can earn on certain patients.
NEW YORK, Oct. 29, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Zacks.com highlights: Manulife Financial, Jazz Pharmaceuticals, DaVita, American Axle & Manufacturing Holdings and Huntsman
Zacks.com featured highlights include: Bausch Health, Endava, DaVita, Perspecta and Athene Holding